Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unjha FormulationsBOM:531762 +4.99%69 Interest Coverage is 143.64 as of Jun. 2026, which is 1555% above its 10-year median of 8.68. GuruFocus rates BOM:531762 with a GF Score™ of 69/100 and a GF Value™ of ₹22.87 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 677 Drug Manufacturers companies, Unjha Formulations ranks better than 77.4% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Unjha Formulations's
Operating Income
for the
three
months ended in Jun. 2026 was ₹1.6 Mil. Unjha Formulations's Interest Expense for the
three
months ended in Jun. 2026 was ₹-0.0 Mil.
Unjha Formulations's interest coverage for the quarter that ended in Jun. 2026 was 143.64.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Unjha Formulations Ltd has no debt.
The historical rank and industry rank for Unjha Formulations's Interest Coverage or its related term are showing as below:
BOM:531762'
s Interest Coverage Range Over the Past 10 Years
Min: 1.48 Med: 8.68 Max: 1596
Current: 93.75
BOM:531762's Interest Coverage is ranked better than 77.4% of 677
companies
in the Drug Manufacturers industry
Industry Median: 13.01
vs BOM:531762: 93.75
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Unjha Formulations Interest Coverage Related Terms
Unjha Formulations Interest Coverage Historical Data
* Premium members only.
The historical data trend for Unjha Formulations's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Unjha Formulations's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unjha Formulations Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Unjha Formulations's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Unjha Formulations's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unjha Formulations (BOM:531762) has a Interest Coverage of 143.64 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Unjha Formulations and its competitors. This is 1555% above median its historical median of 8.68. Over the past decade, Unjha Formulations' Interest Coverage has ranged from 1.48 to 1,596.00. According to the industry distribution chart, Unjha Formulations ranks #153 out of 677 companies in the Drug Manufacturers industry, placing it in the top 22.6%.
Is Unjha Formulations' Interest Coverage too high?
Unjha Formulations' current Interest Coverage of 143.64 is 1555% above median its 10-year median of 8.68. Over the past 10 years, this metric has ranged from a low of 1.48 to a high of 1,596.00. The Drug Manufacturers industry median Interest Coverage is 13.01. Unjha Formulations' value of 143.64 is 1004.1% above this industry median. Based on the distribution chart, Unjha Formulations ranks #153 out of 677 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Unjha Formulations has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Unjha Formulations' Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Unjha Formulations ranks #153 out of 677 companies for Interest Coverage. This places Unjha Formulations in the top 23% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.01. Unjha Formulations' value of 143.64 is 1004.1% above this benchmark. Historically, Unjha Formulations' own Interest Coverage has ranged from 1.48 to 1,596.00 over the past decade. While the company's 10-year median is 8.68 vs. the industry median of 13.01, Unjha Formulations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.01, based on 677 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unjha Formulations's current Interest Coverage of 143.64 is 1004.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Unjha Formulations and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unjha Formulations's current Interest Coverage is 143.64, which is 1555% above median its own 10-year median of 8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unjha Formulations stock overvalued right now?
Based on GuruFocus' analysis, Unjha Formulations (BOM:531762) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹22.87, compared to a current price of ₹32.17 — trading 40.7% above its estimated fair value. The current Interest Coverage is 143.64, which is 1555% above median its 10-year median of 8.68 and 1004.1% above the Drug Manufacturers industry median of 13.01. Unjha Formulations' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Unjha Formulations (BOM:531762), the current Interest Coverage is 143.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Unjha Formulations (BOM:531762) Overvalued in 2026?
Based on GuruFocus' analysis, Unjha Formulations stock appears to be overvalued.
The current stock price of ₹32.17 is trading 40.7% above its estimated GF Value™ of ₹22.87.
GuruFocus considers Unjha Formulations to be Significantly Overvalued.
Key valuation signals for BOM:531762:
Interest Coverage: 143.64 (1555% above median its 10-year median of 8.68)
GF Value™: ₹22.87 vs. price of ₹32.17 (40.7% above fair value)
Industry Position: 1004.1% above the Drug Manufacturers median (#153 of 677)
No single metric tells the full story. See the BOM:531762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Unjha Formulations Ltd is an India-based manufacturer and exporter of Ayurvedic products. The company products include Isabgol powder under the Fibron and Fibron SF name, and Sat-Isabgol and Isabgol Husk. It also offers human and veterinary medicines.
69GF Score
Get the complete analysis for BOM:531762
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531762 has been successfully added to your 
